Business news

    Immutep (ASX:IMM) announces cancer data accepted for European congress

    Article Image

    Immutep (ASX:IMM) has announced that data from the TACTI-002 Phase II trial of eftilagimod alpha in combination with pembrolizumab for 2nd line PD-X refractory non-small cell lung cancer patients has been accepted for a Mini Oral presentation at ESMO’s European Lung Cancer Congress (ELCC) 2023.

    The study showed that 83% of patients experienced deceleration or shrinkage of target lesions, with an overall response rate (ORR) of 8.3% and Disease Control Rate (DCR) of 33%, with responses being durable for 19+ months.

    Final data on safety and efficacy, including overall survival (OS), will be presented at the Mini Oral presentation.

    Immutep's share price is up 2.6% the past five days. 

     

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa